View Single Post
Old 05-16-2019, 04:35 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,915
Default BOOK CHAPTER: HSCT for Autoimmune Diseases—Specific Diseases and Controversies

Autologous Hematopoietic Cell Transplants for
Autoimmune Diseases: Specific Diseases and

L.C.M. Arruda, M.C. Oliveira, K.C.R. Malmegrim, E. Gluckman, and D. Farge

Autologous hematopoietic cell transplantation (auto-HCT) has been intensely investigated as a new therapeutic approach for autoimmune diseases (ADs). Almost 20 years after the first transplant, concise data show that auto-HCT can induce longterm disease stabilization and this new therapeutic approach has been increasingly accepted in several ADs for its combination of safety and efficacy[1–5]. More than 2000 AD patients worldwide (European Blood and Marrow Transplant (EBMT), Center for International Blood and Marrow Research (CIBMTR), Asian registry) have already undergone hematopoietic cell transplantation, mainly autologous, for treatment of AD[3–12], including multiple sclerosis (MS)[13–28], systemic sclerosis (SSc)[29–34], Crohn’s disease (CD)[35–39], systemic lupus erythematosus (SLE)[40–44], and type 1 diabetes (T1D)[45–47], among others[3,5,7,8,48].

Dave Bexfield
Reply With Quote